NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats

[1]  H. Reichmann,et al.  Levodopa in the treatment of Parkinson's disease: Current controversies , 2005, Movement disorders : official journal of the Movement Disorder Society.

[2]  I. Whishaw,et al.  Drug-induced rotation intensity in unilateral dopamine-depleted rats is not correlated with end point or qualitative measures of forelimb or hindlimb motor performance , 2002, Neuroscience.

[3]  K. Fuxe,et al.  The Selective mGlu5 Receptor Agonist CHPG Inhibits Quinpirole-Induced Turning in 6-Hydroxydopamine-Lesioned Rats and Modulates the Binding Characteristics of Dopamine D2 Receptors in the Rat Striatum Interactions with Adenosine A2a Receptors , 2001, Neuropsychopharmacology.

[4]  Erwan Bezard,et al.  Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies , 2001, Nature Reviews Neuroscience.

[5]  M. Zigmond,et al.  Forced Limb-Use Effects on the Behavioral and Neurochemical Effects of 6-Hydroxydopamine , 2001, The Journal of Neuroscience.

[6]  J. Greenamyre.  Glutamatergic influences on the basal ganglia. , 2001, Clinical neuropharmacology.

[7]  Cristina Tassorelli,et al.  Functional changes of the basal ganglia circuitry in Parkinson's disease , 2000, Progress in Neurobiology.

[8]  Chase Tn,et al.  Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. , 2000 .

[9]  S. Fahn,et al.  Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint , 1999, Movement disorders : official journal of the Movement Disorder Society.

[10]  S. Wachtel,et al.  Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions , 1999, Neuroscience.

[11]  J. Brotchie,et al.  Antiparkinsonian Actions of Blockade of NR2B-Containing NMDA Receptors in the Reserpine-Treated Rat , 1999, Experimental Neurology.

[12]  J. Obeso,et al.  Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection , 1998, Annals of neurology.

[13]  Anders Björklund,et al.  Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat , 1998, Experimental Neurology.

[14]  M. Starr,et al.  Stimulation of basal and l-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease , 1997, Neuroscience & Biobehavioral Reviews.

[15]  T. Klockgether,et al.  Effects of the antiparkinsonian drug budipine on central neurotransmitter systems. , 1996, European journal of pharmacology.

[16]  J. Brotchie,et al.  Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: Functional implications for treatment of parkinsonian symptoms , 1995, Psychopharmacology.

[17]  A. Björklund,et al.  Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[18]  P. Bédard,et al.  Intranigral but not intrastriatal microinjection of the NMDA antagonist MK-801 induces contralateral circling in the 6-OHDA rat model , 1994, Brain Research.

[19]  T. Engber,et al.  Excitatory amino acid receptor antagonists modify regional cerebral metabolic responses to levodopa in 6-hydroxydopamine-lesioned rats , 1994, Neuroscience.

[20]  T. Klockgether,et al.  NMDA antagonists potentiate antiparkinsonian actions of L‐dopa in monoamine‐depleted rats , 1990, Annals of neurology.

[21]  G. Di Chiara,et al.  MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease. , 1990, European journal of pharmacology.

[22]  A. Carlsson,et al.  Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease , 1990, Trends in Neurosciences.

[23]  G. Breese,et al.  Long-term D1-dopamine receptor sensitization in neonatal 6-OHDA-lesioned rats is blocked by an NMDA antagonist , 1990, Brain Research.

[24]  C. Négre.  [Treatment of Parkinson's disease]. , 1986, Soins; la revue de reference infirmiere.

[25]  U. Ungerstedt,et al.  Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. , 1970, Brain research.

[26]  O. Hornykiewicz.  Dopamine (3-hydroxytyramine) and brain function. , 1966, Pharmacological reviews.

[27]  W. Danysz,et al.  Memantine, amantadine, and L-deprenyl potentiate the action of L-DOPA in monoamine-depleted rats , 2005, Journal of Neural Transmission / General Section JNT.

[28]  A. Carlsson,et al.  The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice , 2005, Journal of Neural Transmission.

[29]  A. Carlsson,et al.  Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice , 2005, Journal of Neural Transmission.

[30]  S. Ferré,et al.  The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. , 2001, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[31]  T. Chase,et al.  Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. , 2000, Annals of neurology.

[32]  A. Mele,et al.  The role of striatal dopaminergic mechanisms in rotational behavior induced by phencyclidine and phencyclidine-like drugs , 1998, Psychopharmacology.

[33]  W. Danysz,et al.  Are NMDA antagonistic properties relevant for antiparkinsonianlike activity in rats?—Case of amantadine and memantine , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[34]  M. Starr,et al.  Glutamate antagonists modify the motor stimulant actions of D1 and D2 agonists in reserpine-treated mice in complex ways that are not predictive of their interactions with the mixed D1/D2 agonist apomorphine , 1993, Journal of neural transmission. Parkinson's disease and dementia section.

[35]  G. Di Chiara,et al.  Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression. , 1992, The Journal of pharmacology and experimental therapeutics.

[36]  T. Schallert,et al.  A Clinically Relevant Unilateral Rat Model of Parkinsonian Akinesia , 1992, Journal of Neural Transplantation & Plasticity.

[37]  K. Lange,et al.  Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease , 1991, Journal of neural transmission. Parkinson's disease and dementia section.

[38]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[39]  B. Clineschmidt,et al.  Anticonvulsant activity of (+)‐5‐methyl‐10, 11‐dihydro‐5H‐dibenzo[a, d]cyclohepten‐5, 10‐imine (MK‐801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties , 1982 .

[40]  Bradley V. Clineschmidt,et al.  Central sympathomimetic activity of (+)‐5‐methyl‐10,11‐dihydro‐5H‐dibenzo [a, d]cyclohepten‐5,10‐imine (MK‐801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties , 2022 .